Biotech Values

[DewDiligence]

NVS provides Arzerra to US CLL patients at zero cost—pays $30M to GMAB to compensate it for lost royalties on sales:

https://www.globenewswire.com/news-release/2020/08/20/2081670/0/en/Genmab-Announces-Plan-to-Transition-Arzerra-ofatumumab-to-an-Oncology-Access-Program-for-Chronic-Lymphocytic-Leukemia-Patients-in-the-U-S.html

I don’t think it’s a coincidence that this decision comes on the same day the FDA approves Kesimpta (#msg-157767315), but I’m not sure I understand NVS’ logic.